Timothy D. Lyon, MD

"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD.

"The objective of this project [was] to clinically adjudicate the complications identified by that outpatient software," says Timothy D. Lyon, MD.

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD.

"At Mayo Clinic, we think that delivering intravesical therapy for non-muscle invasive bladder cancer in patients' homes has the potential to reduce treatment burden, improve the patient experience, as well as increase access to care," says Timothy D. Lyon, MD.